drugset / Trial / NCT05544929
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
Timeline
- Start
- 2022-10-26
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KFA115 | Unknown | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |